Copyright
©The Author(s) 2026.
World J Clin Cases. Jan 6, 2026; 14(1): 112021
Published online Jan 6, 2026. doi: 10.12998/wjcc.v14.i1.112021
Published online Jan 6, 2026. doi: 10.12998/wjcc.v14.i1.112021
Figure 1 Therapy discontinuation strategies and evidence in Crohn’s disease.
6-MP: 6-mercaptopurine; AI: Artificial intelligence; ASA: Aminosalycilic acid; CD: Crohn’s disease; CN: Crohn’s disease non-responder; CRP: C-reactive protein; FC: Fecal calprotectine; Hb: Hemoglobin; UC: Ulcerative colitis; US: Ultrasonography; WBC: White blood cell.
- Citation: Greco S, Campigotto M, Fabbri N. Discontinuation of advanced therapy in inflammatory bowel disease: Updated evidence, guidelines, and personalized decision-making one year later. World J Clin Cases 2026; 14(1): 112021
- URL: https://www.wjgnet.com/2307-8960/full/v14/i1/112021.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v14.i1.112021
